These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22165858)

  • 1. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
    Valdameri G; Genoux-Bastide E; Peres B; Gauthier C; Guitton J; Terreux R; Winnischofer SM; Rocha ME; Boumendjel A; Di Pietro A
    J Med Chem; 2012 Jan; 55(2):966-70. PubMed ID: 22165858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
    Winter E; Devantier Neuenfeldt P; Chiaradia-Delatorre LD; Gauthier C; Yunes RA; Nunes RJ; Creczynski-Pasa TB; Di Pietro A
    J Med Chem; 2014 Apr; 57(7):2930-41. PubMed ID: 24611893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
    Winter E; Lecerf-Schmidt F; Gozzi G; Peres B; Lightbody M; Gauthier C; Ozvegy-Laczka C; Szakacs G; Sarkadi B; Creczynski-Pasa TB; Boumendjel A; Di Pietro A
    J Med Chem; 2013 Dec; 56(24):9849-60. PubMed ID: 24304387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
    Jabor Gozzi G; Bouaziz Z; Winter E; Daflon-Yunes N; Aichele D; Nacereddine A; Marminon C; Valdameri G; Zeinyeh W; Bollacke A; Guillon J; Lacoudre A; Pinaud N; Cadena SM; Jose J; Le Borgne M; Di Pietro A
    J Med Chem; 2015 Jan; 58(1):265-77. PubMed ID: 25272055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-halogenochromones bearing tryptamine: one-step access to potent and highly selective inhibitors of breast cancer resistance protein.
    Valdameri G; Genoux-Bastide E; Gauthier C; Peres B; Terreux R; Winnischofer SM; Rocha ME; Di Pietro A; Boumendjel A
    ChemMedChem; 2012 Jul; 7(7):1177-80. PubMed ID: 22615192
    [No Abstract]   [Full Text] [Related]  

  • 6. Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2).
    Boumendjel A; Nicolle E; Moraux T; Gerby B; Blanc M; Ronot X; Boutonnat J
    J Med Chem; 2005 Nov; 48(23):7275-81. PubMed ID: 16279786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.
    Gozzi GJ; Bouaziz Z; Winter E; Daflon-Yunes N; Honorat M; Guragossian N; Marminon C; Valdameri G; Bollacke A; Guillon J; Pinaud N; Marchivie M; Cadena SM; Jose J; Le Borgne M; Di Pietro A
    Drug Des Devel Ther; 2015; 9():3481-95. PubMed ID: 26170632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.
    Valdameri G; Gauthier C; Terreux R; Kachadourian R; Day BJ; Winnischofer SM; Rocha ME; Frachet V; Ronot X; Di Pietro A; Boumendjel A
    J Med Chem; 2012 Apr; 55(7):3193-200. PubMed ID: 22449016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of inhibitors of BCRP/ABCG2.
    Juvale K; Wiese M
    Future Med Chem; 2015 Aug; 7(12):1521-7. PubMed ID: 26293476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.
    Darby RA; Unsworth A; Knapp S; Kerr ID; Callaghan R
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):853-64. PubMed ID: 26351135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2.
    Roussel E; Moréno A; Altounian N; Philouze C; Pérès B; Thomas A; Renaudet O; Falson P; Boumendjel A
    Eur J Med Chem; 2020 Sep; 202():112503. PubMed ID: 32653696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
    Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2.
    Pires ADRA; Lecerf-Schmidt F; Guragossian N; Pazinato J; Gozzi GJ; Winter E; Valdameri G; Veale A; Boumendjel A; Di Pietro A; Pérès B
    Eur J Med Chem; 2016 Oct; 122():291-301. PubMed ID: 27376492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.
    Kuang YH; Patel JP; Sodani K; Wu CP; Liao LQ; Patel A; Tiwari AK; Dai CL; Chen X; Fu LW; Ambudkar SV; Korlipara VL; Chen ZS
    Biochem Pharmacol; 2012 Sep; 84(6):766-74. PubMed ID: 22750060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.
    Bram E; Ifergan I; Shafran A; Berman B; Jansen G; Assaraf YG
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):826-34. PubMed ID: 16612649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABCG2: recent discovery of potent and highly selective inhibitors.
    Lecerf-Schmidt F; Peres B; Valdameri G; Gauthier C; Winter E; Payen L; Di Pietro A; Boumendjel A
    Future Med Chem; 2013 Jun; 5(9):1037-45. PubMed ID: 23734686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.
    Valdameri G; Pereira Rangel L; Spatafora C; Guitton J; Gauthier C; Arnaud O; Ferreira-Pereira A; Falson P; Winnischofer SM; Rocha ME; Tringali C; Di Pietro A
    ACS Chem Biol; 2012 Feb; 7(2):322-30. PubMed ID: 22039929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.